Literature DB >> 11005454

Sexual function and fertility after treatment of testicular cancer.

M Kuczyk1, S Machtens, C Bokemeyer, D Schultheiss, U Jonas.   

Abstract

As a result of the introduction of effective cisplatin-based chemotherapeutic regimens into the clinical routine, even patients with metastatic testicular cancer at initial diagnosis can be cured of their disease. Sexual dysfunction and infertility are common long-lasting sequelae in testicular cancer survivors, affecting approximately 20% of patients after the application of the different treatment modalities currently available for the treatment of early and advanced clinical stages, including retroperitoneal surgery and systemic chemotherapy. Accordingly, it has been demonstrated that fertility distress and sexual disturbances, the latter occurring in only a minority of patients after surgical or chemotherapeutic treatment of testicular germ cell tumours, substantially alter the patients' quality of life. It is even worse because testicular cancer mostly affects men in the prime of their physical, sexual and reproductive function. Although semen quality is frequently poor at initial diagnosis and further deteriorates after orchiectomy, probably because of structural abnormalities in the remaining contralateral testicle, the advent of intracytoplasmatic sperm injection promises a fertile future to most patients, even if only a few sperms are present in the ejaculate. Further long-term investigations should be initiated to clarify the impact of the different treatment modalities on fertility and sexual life. The main objective should be the identification of patients who are at increased risk of developing therapy-related physical and psychological problems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005454     DOI: 10.1097/00042307-200009000-00018

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  7 in total

1.  Genome instability in AZFc region on Y chromosome in leukocytes of fertile and infertile individuals following exposure to gamma radiation.

Authors:  Sahar Moghbeli-Nejad; Hossein Mozdarani; Mehrdad Behmanesh; Zahra Rezaiean; Parvin Fallahi
Journal:  J Assist Reprod Genet       Date:  2011-09-06       Impact factor: 3.412

2.  Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors.

Authors:  Ahmet Alacacioglu; Eda Ulger; Umut Varol; Tugba Yavuzsen; Murat Akyol; Yasar Yildiz; Ibrahim Yildiz; Vedat Bayoglu; Ahmet Dirican; Lutfiye Demir; Tarik Salman; Yuksel Kucukzeybek; Inci Alacacioglu; Huseyin Can; Mustafa Oktay Tarhan
Journal:  Med Oncol       Date:  2014-06-10       Impact factor: 3.064

3.  Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26.

Authors:  Bernhard Holzner; Fabio Efficace; Umberto Basso; Colin D Johnson; Neil K Aaronson; Juan I Arraras; Allan B Smith; Edward Chow; Anne S Oberguggenberger; Andrew Bottomley; Hannes Steiner; Luca Incrocci; Johannes M Giesinger
Journal:  Qual Life Res       Date:  2012-03-10       Impact factor: 4.147

Review 4.  The Clinician's Toolbox: Assessing the Sexual Impacts of Cancer on Adolescents and Young Adults with Cancer (AYAC).

Authors:  Sylvie Aubin; Samara Perez
Journal:  Sex Med       Date:  2015-07-30       Impact factor: 2.491

5.  The rates of premature chromosome condensation and embryo development after injection of irradiated sperms into hamster oocytes.

Authors:  Sahar Moghbelinejad; Hossein Mozdarani; Zahra Rezaeian
Journal:  Iran J Reprod Med       Date:  2013-05

Review 6.  The primary health care physician and the cancer patient: tips and strategies for managing sexual health.

Authors:  Eric S Zhou; Larissa Nekhlyudov; Sharon L Bober
Journal:  Transl Androl Urol       Date:  2015-04

7.  The effect of gonadal and extragonadal malignant cancers on sperm quality.

Authors:  Xiao Liu; Bo Liu; Shasha Liu; Yang Xian; Wenrui Zhao; Min Jiang; Bin Zhou; Fuping Li
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.